Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $348.9 million.

  • Arcutis Biotherapeutics' Liabilities and Shareholders Equity fell 15.18% to $371.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 16.78%. This contributed to the annual value of $348.9 million for FY2024, which is 2.20% up from last year.
  • As of FY2024, Arcutis Biotherapeutics' Liabilities and Shareholders Equity stood at $348.9 million, which was up 2.20% from $341.4 million recorded in FY2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Liabilities and Shareholders Equity peaked at $449.3 million during FY2022, and registered a low of $298.3 million during FY2020.
  • Over the past 3 years, Arcutis Biotherapeutics' median Liabilities and Shareholders Equity value was $348.9 million (recorded in 2024), while the average stood at $379.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 36.84% in 2021, then declined by 24.02% in 2023.
  • Arcutis Biotherapeutics' Liabilities and Shareholders Equity (Yearly) stood at $298.3 million in 2020, then skyrocketed by 36.84% to $408.2 million in 2021, then grew by 10.08% to $449.3 million in 2022, then fell by 24.02% to $341.4 million in 2023, then rose by 2.20% to $348.9 million in 2024.